Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5326303 | 1.00 | PAX8 (0.41) | PAX8LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL1303718 | 0.90 | PAX8 (0.41) | PAX8LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL3421053 | 0.84 | LMNA (0.39) | PAX8LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL3419152 | 0.84 | LMNA (0.39) | PAX8LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL3419233 | 0.84 | LMNA (0.39) | PAX8LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL3414678 | 0.83 | LMNA (0.38) | PAX8LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL3415356 | 0.83 | LMNA (0.38) | PAX8LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL3421254 | 0.83 | LMNA (0.38) | PAX8LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL3414706 | 0.83 | LMNA (0.38) | PAX8LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL3421343 | 0.83 | LMNA (0.38) | PAX8LMNAL3MBTL1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720291-A1 | METHODS FOR DIRECTING LIPID NANOPARTICLES IN VIVO | Vertex Pharmaceuticals Incorporated (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260078381-A1 | Methods for Directing Lipid Nanoparticles in Vivo | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-03-19 | — | — | US | claimed |
| US-20250146001-A1 | Compositions and Methods for Enhancing AAV Therapy and Decreasing Tropism of AAV to the Liver | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-08 | — | — | US | claimed |
| EP-4511485-A1 | COMPOSITIONS AND METHODS FOR ENHANCING AAV THERAPY AND DECREASING TROPISM OF AAV TO THE LIVER | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | claimed |
| WO-2024249354-A1 | METHODS FOR DIRECTING LIPID NANOPARTICLES IN VIVO | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| EP-4380624-A1 | MULTIVALENT LIGAND CLUSTERS WITH DIAMINE SCAFFOLD FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2024-06-12 | — | — | EP | claimed |
| WO-2023205606-A1 | COMPOSITIONS AND METHODS FOR ENHANCING AAV THERAPY AND DECREASING TROPISM OF AAV TO THE LIVER | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | claimed |
| WO-2023045995-A1 | Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-03-30 | — | — | WO | claimed |
| US-20220175934-A1 | MULTIVALENT LIGAND CLUSTERS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | MITOTHERAPEUTIX LLC | 2022-06-09 | — | — | US | claimed |
| WO-2014179445-A1 | COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE | Regulus Therapeutics Inc. (US) | 2014-11-06 | — | — | WO | claimed |
| WO-2014179446-A2 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122 | Regulus Therapeutics Inc. (US) | 2014-11-06 | — | — | WO | claimed |
| WO-2014089146-A1 | COMPOSITIONS AND METHODS FOR IN VIVO DELIVERY OF ANTISENSE COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | claimed |
| EP-2658579-A2 | IN VIVO POLYNUCLEOTIDE DELIVERY CONJUGATES HAVING ENZYME SENSITIVE LINKAGES | Arrowhead Research Corporation (US) | 2013-11-06 | — | — | EP | claimed |
| US-20130281658-A1 | Peptide-Based In Vivo siRNA Delivery System | Arrowhead Pharmaceuticals, Inc. | 2013-10-24 | — | — | US | claimed |
| US-8501930-B2 | Peptide-based in vivo siRNA delivery system | Arrowhead Madison Inc. (US) | 2013-08-06 | — | — | US | claimed |
| US-8426554-B2 | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages | Arrowhead Madison Inc. (US) | 2013-04-23 | — | — | US | claimed |
| WO-2012092373-A2 | IN VIVO POLYNUCLEOTIDE DELIVERY CONJUGATES HAVING ENZYME SENSITIVE LINKAGES | ARROWHEAD RESEARCH CORPORATION (US) | 2012-07-05 | — | — | WO | claimed |
| US-20120172412-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | Arrowhead Madison Inc. (US) | 2012-07-05 | — | — | US | claimed |
| US-20120165393-A1 | Peptide-Based In Vivo siRNA Delivery System | Arrowhead Madison Inc. (US) | 2012-06-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165393-A1 | Peptide-Based In Vivo siRNA Delivery System | VIP, RNASE1, APLNR | PAX8 3409/4885LMNA 811/4885L3MBTL1 925/4885 |
| US-20120172412-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | RNASE1, PNKP, POLM | PAX8 4018/4885LMNA 389/4885L3MBTL1 1892/4885 |
| US-20220175934-A1 | MULTIVALENT LIGAND CLUSTERS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | ATIC, PCNA, FOLR1 | PAX8 1628/4885LMNA 3132/4885L3MBTL1 447/4885 |
| US-20260078381-A1 | Methods for Directing Lipid Nanoparticles in Vivo | LDLR, APOL1, APOB | PAX8 2397/4885LMNA 216/4885L3MBTL1 100/4885 |
| US-20130281658-A1 | Peptide-Based In Vivo siRNA Delivery System | VIP, RNASE1, APLNR | PAX8 3409/4885LMNA 811/4885L3MBTL1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.